Clinical outcomes of the proximal optimisation technique (POT) in bifurcation stenting
- PMID: 33970107
- PMCID: PMC9724857
- DOI: 10.4244/EIJ-D-20-01393
Clinical outcomes of the proximal optimisation technique (POT) in bifurcation stenting
Abstract
Background: Optimal deployment of coronary stents in a bifurcation lesion remains a matter of debate.
Aims: We sought to capture the daily practice of bifurcation stenting by means of a worldwide registry and to investigate how post-implantation deployment techniques influence clinical outcomes.
Methods: Data from the e-ULTIMASTER registry were used to perform an analysis of 4,395 patients undergoing percutaneous coronary intervention for bifurcation lesions. Inverse probability of treatment weights (IPTW) propensity score methodology was used to adjust for any baseline differences. The primary outcome of interest was target lesion failure (TLF) at one year (follow-up rate 96.2%).
Results: The global one-year TLF rate was low (5.1%). The proximal optimisation technique (POT) was used in 33.9% of cases and was associated with a reduction in the adjusted TLF rate (4.0% [95% confidence interval: 3.0-5.1%] vs 6.0% [5.1-6.9%], p<0.01) due to a reduction of all components of this composite endpoint, except for cardiac death. Stent thrombosis was also positively impacted (0.4% [0.04-0.7%] vs 1.3% [0.8-1.7%], p<0.01). POT benefit was uniform across subgroups. Conversely, the use of the kissing balloon technique (36.5%) did not influence the adjusted TLF rate.
Conclusions: Despite a low one-year failure rate in this large bifurcation stenting cohort, POT was associated with a further reduction in the event rate and a uniform benefit across subgroups, suggesting systematic use of this deployment technique regardless of the bifurcation anatomy and stenting technique.
Conflict of interest statement
B. Chevalier reports grants from Terumo during the conduct of the study, personal fees from Terumo, outside the submitted work, and being a minor shareholder of CERC (CRO). M. Mamas has the following interests to declare: unrestricted educational grants from Terumo, Abbott, Medtronic and Biosensors, and speaker fees from Terumo, Daiichi Sankyo and Biosensors. M. Pan reports minor lecture fees from Abbott, Terumo and Volcano. F.F. Beygui reports grants from Terumo during the conduct of the study, grants and personal fees from Medtronic and Biosensor, and personal fees from Bristol Myers Squibb, outside the submitted work. The other authors have no conflicts of interest to declare.
Figures
References
-
- Louvard Y, Thomas M, Džavík V, Hildick-Smith D, Galassi AR, Pan M, Burzotta F, Zelizko M, Dudek D, Ludman P, Sheiban I, Lassen JF, Darremont O, Kastrati A, Ludwig J, Iakovou I, Brunel P, Lansky A, Meerkin D, Legrand V, Medina A, Lefevre T. Classification of coronary artery bifurcation lesions and treatments: time for a consensus! Catheter Cardiovasc Interv. 2008;71:175–83. doi: 10.1002/ccd.21314. - DOI - PubMed
-
- Lassen JF, Holm NR, Stankovic G, Lefevre T, Chieffo A, Hildick-Smith D, Pan M, Darremont O, Albiero R, Ferenc M, Louvard Y. Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings. EuroIntervention. 2014;10:545–60. doi: 10.4244/EIJV10I5A97. - DOI - PubMed
-
- Hildick-Smith D, Lassen JF, Albiero R, Lefevre T, Darremont O, Pan M, Ferenc M, Stankovic G, Louvard Y European Bifurcation Club. Consensus from the 5th European Bifurcation Club meeting. EuroIntervention. 2010;6:34–8. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
